Adverse Events Induced by Nivolumab Plus Ipilimumab vs. Nivolumab Monotherapy among Cancer Patients: A Systematic Review and Meta-Analysis

被引：2

作者：

Kamat, Shweta ^{[1
]}

Patel, Jay ^{[1
]}

Brown, Britny R. ^{[1
]}

Vyas, Ami ^{[1
]}

机构：

[1] Univ Rhode Isl, Coll Pharm, Dept Pharm Practice, 7 Greenhouse Rd, Kingston, RI 02881 USA

来源：

CANCER INVESTIGATION | 2022年 / 40卷 / 09期

基金：

美国国家卫生研究院;

关键词：

Nivolumab; ipilimumab; immune checkpoint inhibitors; adverse events; meta-analysis; STAGE IV MELANOMA; PREDICTIVE BIOMARKERS; ADJUVANT NIVOLUMAB; DOUBLE-BLIND; IMMUNOTHERAPY;

D O I：

10.1080/07357907.2022.2108827

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A systematic review and meta-analysis of randomized controlled trials (RCTs) were performed to examine treatment-related adverse events (TRAEs) for combination of nivolumab (NIVO) and ipilimumab (IPI) compared to NIVO monotherapy among cancer patients. We searched several databases to identify relevant RCTs. Meta-analysis was performed using random-effects model. In fourteen RCTs included in the study, we found that compared to NIVO monotherapy, combination NIVO + IPI increased the risk of any grade (Risk Ratio (RR) = 1.11), and grade 3 or 4 (RR = 1.95) TRAEs. Compared to NIVO, NIVO + IPI had higher risk for any grade colitis (RR = 4.52), pneumonitis (RR = 3.06), and diarrhea (RR = 1.68).

引用

页码：777 / 788

页数：12

共 50 条

[1] INCIDENCE OF ADVERSE EVENTS AMONG CANCER PATIENTS TREATED WITH NIVOLUMAB WITH IPILIMUMAB VERSUS NIVOLUMAB MONOTHERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS
Vyas, A.
Patry, E. J.
Albatal, C.
Rogala, B.
VALUE IN HEALTH, 2019, 22 : S61 - S61
[2] Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis
Zhao, Xin
Gao, Fengwei
Yang, Jie
Fan, Hua
Xie, Qingyun
Jiang, Kangyi
Gong, Jie
Gao, Benjian
Yang, Qian
Lei, Zehua
FRONTIERS IN ONCOLOGY, 2022, 12
[3] Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis
Yang, Yi
Jin, Gang
Pang, Yao
Huang, Yijie
Wang, Wenhao
Zhang, Hongyi
Tuo, Guangxin
Wu, Peng
Wang, Zequan
Zhu, Zijiang
FRONTIERS IN PHARMACOLOGY, 2020, 11
[4] Efficacy and safety of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced melanoma: a systematic review and meta-analysis
Cui, Shuting
Sun, Xiaozhe
Gao, Junxi
EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (05) : 283 - 291
[5] Treatment-related gastrointestinal adverse events of nivolumab plus ipilimumab in randomized clinical trials: a systematic review and meta-analysis
Liu, Ke
Wang, Yong-Hong
Luo, Na
Gong, Juan
Wang, Jun
Chen, Bing
FUTURE ONCOLOGY, 2023, 19 (27) : 1865 - 1875
[6] Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
Jiang, Huihui
Xu, Aiqun
Xia, Wanli
Xia, Xingyuan
Li, Pulin
Zhang, Binbin
Zhu, Ke
Zhou, Sijing
Wang, Ran
CANCER CELL INTERNATIONAL, 2021, 21 (01)
[7] Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis
Huihui Jiang
Aiqun Xu
Wanli Xia
Xingyuan Xia
Pulin Li
Binbin Zhang
Ke Zhu
Sijing Zhou
Ran Wang
Cancer Cell International, 21
[8] Efficacy and safety of nivolumab plus ipilimumab in gastrointestinal cancers: a systematic review and meta-analysis
Dai, Bowen
Jiang, Jiaping
Yu, Xiaoyu
Zhan, Haihua
Hu, Zhengchuan
FRONTIERS IN ONCOLOGY, 2025, 14
[9] Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma A Meta-Analysis
Serritella, Anthony V.
Shenoy, Niraj K.
JAMA ONCOLOGY, 2023, 9 (10) : 1441 - 1446
[10] Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
Almutairi, Abdulaali R.
McBride, Ali
Slack, Marion
Erstad, Brian L.
Abraham, Ivo
FRONTIERS IN ONCOLOGY, 2020, 10

← 1 2 3 4 5 →